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A 33-year-old man was admitted to the Nephrology Department at the
Hospital General Universitario Gregorio Marafión because of progressive
renal failure, severe anemia, and intense fatigue.
At age 29, gross hematuria for several days followed by ankle edema
prompted study at another center. He was normotcnsive and his renal
function was normal (serum creatinine, 1.2 mg/dl; creatinine clearance, 95
mI/mm). The 24-hour urinary protein excretion was 7.3 g. Serum total
protein was 4 g/dl and serum albumin was 1.5 g/dl. Renal biopsy was
performed; light microscopic examination revealed diffuse and uniform
thickening of the capillary wall, without cell proliferation. There was mild
interstitial infiltration by mononuclear cells. Silver methenamine staining
revealed the presence of spikes. Immunofluorescent examination showed
uniform granular deposits of IgG and C3 outlining all the capillary loops.
A histopathologic diagnosis of membranous nephropathy was made.
Antinuclear antibodies and anti-DNA antibodies were negative, as was
hepatitis B viral antigen testing. An abdominal CT scan was normal. A
diagnosis of nephrotic syndrome secondary to idiopathic mcmbranous
nephropathy (with normal renal function) was made, and the patient was
treated conservatively with a low-salt diet.
One year later, at age 30, the serum creatinine was 1.8 mg/dl and urinary
protein excretion remained greater than 7 g/day. At age 32, the serum
creatinine was 2.2 mg/dl, and 6 months before admission it rose to 3.3
mg/dl.
When the patient was admitted to our hospital, he presented with
intense fatigue, pallor, and loss of appetite. He had begun to lose weight
and was forced to stop working. The hematocrit was 24.6%; red blood cell
count, 2,800,000/mm3; hemoglobin, 8.3 g/dl; mean corpuscular volume,
87.7 II; white blood cell count, 7200/mm3; and platelet count, 313,000/mm3.
The serum creatinine was 5.3 mg/dl and creatinine clearance 17.4 mI/mm.
Serum ferritin was 190 .rg/liter; iron, 89 jig/dI; transferrin, 195 mg/dl;
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transferrin saturation, 23%; serum vitamin B12, 784 pg/mI; folic acid, 7.7
pg/mI; and eiythropoietin, 15 mIU/ml. Serum PTH was 263 ng/ml; total
protein, 4.6 g/dl; albumin, 2.4 g/dl; total cholesterol, 286 mg/dl; triglycer-
ides, 87 mg/dl; and alkaline phosphatase, 152 U/liter.
There was no evidence of hemorrhage, decreased iron Stores, or folic
acid or vitamin B12 deficiency. Treatment with recombinant human
erythropoietin was begun at a dose of 1000 LU three times per week,
subcutaneously. Ferrous sulfate (270 mg; 80 mg Fe) three times daily
was administered simultaneously.
In the following weeks, the patient began to improve. Two months after
beginning treatment with recombinant human erythropoietin, his hemat-
ocrit was 36%; hemoglobin, 12.1 g/dl; and mean corpuscular volume, 87.7
fi. The patient returned to work and his appetite improved greatly. The
decrease in serum total protein persisted (4.3 g/dl); serum ferritin was 88
jig/liter; and the serum creatinine continued to rise (6.7 mg/dl). Total
serum calcium was 6.7 mg/dl; phosphorus, 5.6 mg/dl; and PTH, 354 pg/mI.
Oral calcitriol was started at a dose of 0.25 jig/day.
The patient maintained that he was taking oral ferrous sulfate as
prescribed, hut 6 months after the beginning of treatment with erythro-
poietin, the serum ferritin had fallen to 3 jig/liter. His hematocrit fell to
26%, hemoglobin to 8.9 g/dl, and mean corpuscular volume to 82.2 11. Oral
administration of ferrous sulfate was stopped, and treatment with intra-
venous ferrous gluconate was initiated; a dose of 62.5 mg, diluted in 250
ml of 5% dextrose (administered over one hour) was repeated every week.
One month later, the hematocrit was 39.6%; hemoglobin, 13.3 g/dI; and
mean corpuscular volume, 88 fi. The serum ferritin increased to 88
jig/liter. Throughout the following months, the dose of recombinant
human eiythropoietin was reduced to 1000 IU twice weekly and later to
once weekly. Administration of intravenous ferrous gluconate (62.5 mg)
was continued every month, and serum ferritin levels exceeded 250
jig/liter. The hematocrit level remained between 33% and 39%.
Sixteen months after the initiation of treatment with recombinant
human erythropoietin, the serum creatinine had increased to 11.5 mg/dl,
and renal replacement therapy was begun using hemodialysis three times
per week. Treatment with erythropoietin and intravenous iron was
continued. Residual renal function decreased after hemodialysis com-
menced; by six months later, the serum total protein was normal.
During the following three years, the patient remained stable and in
good clinical condition, Erythropoietin was given in a dose ranging from
1000 to 2000 LU per week subcutaneously, and ferrous gluconate was
administered every two to four weeks; the aim was to maintain a serum
ferritin level between 100 and 200 jig/liter. His hematocrit remained above
30% and the hemoglobin concentration exceeded 11 g/dl.
At age 38, four years after starting hemodialysis treatment, his hemat-
ocrit fell below 30%; the serum ferritin was between 128 and 215 jig/liter.
The dose of erythropoietin was increased to 4000 LU three times per week.
Nonetheless, his hematoerit fell to 22% and the hemoglobin to 7.3 g/dl,
with a mean corpuscular volume of 89 fi. The PTH level had increased
over the preceding years and by this point was 825 pg/mI. The total serum
calcium was 10.6 mg/dl; phosphorus, 6.5 mg/dl; alkaline phosphatase, 835
U/liter; and serum aluminum, 6 jig/liter. Intravenous calcitriol was started
at a dose of 2 jig three times per week. After three weeks of treatment, the
patient developed intense pruritus; the total serum calcium was 13.5 mg/dl
and intravenous calcitriol was stopped. The hematocrit remained between
20% and 22% with no evidence of hemorrhage; the serum ferritin level
was 180 jig/liter. Gastroscopy revealed normal esophageal and gastric
mucosa. The patient underwent a subtotal parathyroidectomy with re-
moval of the four glands and implantation of ten small fragments of
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parathryoid tissue in the forearm. The total weight of the four glands was
2850 mg. Three months later, his hematocrit had risen to 37%, the PTH
level had fallen to 110 pg/mI, and the dose of erythropoietin was decreased
to 2000 IU three times per week.
Discussion
DR. FERNANDO VALDERRABANO (Professor of Medicine, and
Chairman, Department of Nephrology, Hospital General Universita-
rio Gregorio Marañón, Madrid, Spain): A decade has passed since
the first patients with end-stage renal disease (ESRD) were
treated with recombinant human erythropoietin (Epo). Thou-
sands of patients have received this treatment all over the world
during this time. In Europe, more than 50% of patients receiving
hemodialysis treatment were given Epo therapy in 1992 [1]; in
some European countries, the percentage of patients treated with
Epo was higher than 80%. When Epo use began in 1985, the
objective was to eliminate blood transfusions and thereby the risks
of iron overload, sensitization, and transmission of viral diseases
[2]. In the last few years, however, we have learned that Epo
treatment can improve the feeling of well-being in ESRD patients
and, consequently, their quality of life; Epo also can eliminate
symptoms commonly attributed to uremia but probably the result
of anemia.
However, Epo treatment is costly. Therefore the percentage of
ESRD patients who receive Epo in different countries is a
function of the country's economic level. Abundant clinical expe-
rience has defined the best way to use this hormone to maximize
its benefits and avoid its adverse effects. Even so, aspects of the
optimal use of Epo remain to he elucidated. The varied beneficial
effects of Epo treatment range from improving cognitive and
sexual function to ameliorating left-ventricular hypertrophy. In
the short term, these effects are clearly manifested. Nevertheless,
long-term effects have not yet been determined. Optimal use of
Epo should achieve the greatest benefits at the lowest cost. For
this reason, it is important that we diagnose the conditions that
produce hyporesponsiveness to Epo.
As I said, Epo is efficacious in ESRD patients who are
undergoing renal replacement therapy, but it currently is used
more and more frequently in ESRD patients who have not yet
started dialysis. As in today's case, the main objective of Epo use
in pre-dialysis patients is to maintain the patient free of symptoms
and in the best possible clinical condition; the goal is to enable the
patient to make the transition from severe chronic renal failure
(CRF) to renal replacement therapy with minimal symptoms.
Unanswered questions remain. Does Epo treatment accelerate
the progression of chronic renal failure? Or, to the contrary, can
Epo delay the start of dialysis treatment? The case presentation
shows two aspects of Epo treatment that have not yet been fully
explored. The first is the importance of restoring iron stores in
Epo-treated patients, including pre-dialysis patients. Oral iron
administration is not always sufficient, because iron absorption
can be abnormal in these patients. Available data clearly demon-
strate that intravenous iron administration has a salutary effect on
the response to Epo [3], but this maneuver is rarely necessary in
pre-dialysis patients. In today's patient, intravenous ferrous glu-
conate administration allowed a normalization of serum ferritin
levels, thereby prompting an excellent response to Epo.
A second aspect of the case presentation is the patient's lack of
response to Epo treatment that appeared four years after he
started hemodialysis treatment, and which resulted from severe
secondary hyperparathyroidism. A sixfold increase of the weekly
dose of Epo (4000 IU three times/week) was not successful in
restoring the hematocrit to its previous level. Only parathyroid-
eetomy succeeded in improving the patient's hematocrit and in
allowing us to decrease the dose of Epo. Let us now turn to the
use of Epo in pre-dialysis patients, different causes of hyporespon-
siveness, optimal use of Epo, and its beneficial effects both short-
and long-term, with special emphasis on quality of life and the
target hematocrit.
Epo treatment in pre-dialysis patients
Several groups have reported an improvement in general
clinical status as well as increased appetite and physical activity in
CRF patients treated with Epo before beginning dialysis [4—8].
Symptoms of anemia usually appear when the hematocrit falls to
below 30%, or with higher hematocrit levels if heart failure or
angina pectoris is present. In one study, work capacity increased
significantly—by 62%—in Epo-treated pre-dialysis patients, as
assessed by questionnaires filled out by the patients [4]. We
concur with the authors who maintain that instead of asking
whether these patients should be treated, we should ask, why not?
If beneficial and adverse effects, proven in dialysis patients, are
the same in pre-dialysis patients, the most important potential
hazard is the possibility of worsening renal function.
In a Spanish multicenter study, we treated 34 pre-dialysis
patients. This study consisted of two protocols of treatment; in
Protocol A, Epo was administered by the subcutaneous route at
an initial dose of 75 lU/kg/once weekly. In Protocol B, three doses
of 25 lU/kg were administered every week [8]. Self-administration
of subcutaneous Epo at home was possible after short preparatory
conversations with the patients.
Although daily doses have been used [9], our experience
showed that similar results were obtained when the entire weekly
dose was administered all at once. Patients treated according to
Protocol A (Epo dose administered once weekly) increase their
hemoglobin level from a mean of 8.3 g/dl to 10.7 g/dl at three
months, and patients treated according to Protocol B (three doses
weekly) increased their hemoglobin level from a mean of 7.9 g/dl
to 10.6 g/dl.
Oral iron administration, in the form of ferrous sulfate or
fumarate frequently is enough to support erythropoiesis, but not
all patients tolerate it well, and gastrointestinal absorption is not
always sufficient. In these cases, intravenous iron administration is
necessary, with either iron dextran or iron gluconate. It is possible
that in the patient presented today, edema of the gastrointestinal
mucosa—a consequence of the nephrotic syndrome—caused the
low iron absorption. Chronic renal failure patients with a func-
tioning renal graft who need Epo treatment can have higher iron
requirements as a consequence of the administration of azathio-
prine [6]. However, ferrokinetic studies show that treatment with
azathioprine increases ineffective erythropoiesis: erythrocytes are
destroyed within the bone marrow before maturation and release
[10].
We have not seen any significant variation in arterial blood
pressure or in serum creatinine in pre-dialysis patients treated
with Epo in up to one year followup [8]. There were no differences
in serum creatinine or in blood pressure in pre-dialysis patients
receiving three doses per week compared with those receiving the
total weekly dose at once [8]. Similar results in clinical studies
have been described by other authors [4, 5]. However, we have
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Fig. 1. Slope of the inverse of serum creatinine in a group of pre-dialysis,
Epo-treated patients N = 12), compared to a control group ofpre-dialysis,
non-treated patients (A, N = 15). Note the significant improvement of the
slope in Epo-treated patients (—0.0098 vs. —t).0062 dl/mg month, P <
0.05). There was no significant change in the slope of non-treated patients
(—0.0045 vs. —0.0043 dl/mg month, NS).
seen a decrease of serum ferritin levels three months after starting
treatment, although these patients were receiving oral iron sup-
plements. This is a usual finding reported in hemodialysis patients
treated with Epo [111.
The most important aspect of the use of Epo in pre-dialysis
patients is the possibility of worsening their renal function. In rats
submitted to five-sixths nephrectomy, anemia retarded the pro-
gression of proteinuria and glomerular sclerosis, and also reduced
systemic hypertension. When these animals were treated with
Epo, glomerular injury accelerated and renal failure progressed
rapidly [12]. These animals also showed a considerable increase in
systemic blood pressure. In other animal experiments in which
Epo-induced hypertension was controlled with antihypertensive
drugs, the progression of renal failure was prevented [13].
Human studies have not been able to demonstrate that Epo
treatment in pre-dialysis patients worsens renal function [14—18].
Our first experience in 12 patients, followed for two years before
starting Epo treatment until one-and one-half years after therapy
began, showed no variation in the slope of the inverse of serum
creatininc [18]. To assess whether the improvement in hemoglo-
bin concentration did not have a negative effect on renal function
loss, we selected a group of 12 patients with chronic renal failure
followed for two years before starting the study. They were treated
with low doses of Epo (68 13 lU/kg) once weekly subcutane-
ously. This group of patients was compared with a control group
of 15 patients with chronic renal failure but not treated with Epo.
The progression of renal insufficiency was measured by the slope
of the regression line of the inverse of serum creatinine. We found
no differences in serum creatinine between the groups at the
beginning of treatment (4.7 1.9 mg/dl in the treated group
versus 4.9 1.7 mg/dl in the control group). In the control group,
the slope of the inverse of serum creatinine did not change; in the
Epo-treated group, this slope improved slightly [181 but signifi-
cantly (Fig. 1).
Patients who received Epo treatment had a faster progression
of renal failure during the two years before Epo treatment
compared to the control group. This faster progression likely
would have caused more intense anemia, in fact, the mean
a Mean starting subcutaneous Epo dose: 67.8 20.3 lU/kg/week. PhD,
physical dimension; P5D, psychosocial dimension; OS, global score. Data
as mean error standard of mean. Lower scores mean better quality of
life.
< 0.001.
ap <0.01.
hematocrit when patients began Epo treatment was 24.2%
2.5% compared to 29.5% 3.6% in the control group.
After 15 months of followup, the mean serum creatinine in the
treated group was 7.29 1.8 mgldl, and two of the twelve patients
needed to start dialysis therapy. The mean serum creatinine of the
control group was 6.57 1.8 mg/dl, and three of the fifteen
patients started dialysis (P, NS). We do recognize, however, the
limitations of measuring the progression of renal disease by the
slope of the inverse of serum creatinine [19].
Studies published to date have not been able to demonstrate
that Epo treatment in pre-dialysis patients worsens renal function
[14—18]. An increase in the glomerular filtration fraction seem-
ingly related to an increase in blood pressure was shown in one
study [141. However, in another similar study, in which blood
pressure was carefully controlled, filtration fraction did not in-
crease [15]. Another controlled study did not find deterioration of
renal function when glomerular filtration rate was measured with
'251-iothalamate [17].
If, then, Epo administration does not worsen renal function, we
can ask a related question: Can Epo treatment delay the start of
dialysis? At this moment, we have no clear answer. We do have
evidence that the quality of life of pre-dialysis patients improves
with Epo treatment. In a Spanish multicenter pre-dialysis study,
we used the Sickness Impact Profile (SIP) to measure the quality
of life of these patients. Our results showed that the global score
improved significantly in Epo-treated patients; no variations in
this score occurred in the control group of pre-dialysis patients
who did not receive Epo. Similar results were observed in the
physical dimension and the psycho-social dimension of the same
test. Table 1 summarizes the characteristics of these patients as
well as their hematocrit and hemoglogin levels (pre and post
treatment) and the physical dimension, psycho-social dimension,
and global score of the SIP.
One of the objectives of that study was to determine whether
Epo therapy can delay the start of dialysis. The decision to start
renal replacement therapy is usually based on analytic data but
0
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—24
Table 1. Evolution of the Sickness Impact Profile (SIP) scores in 54
pre-dialysis patients treated with Epo (Epo group) and in 26 pre-
dialysis patients not receiving Epo (Control group)a
Epo group Control group
—12 0 +12
Number 54 26
Mean age (years) 56.4 14.9 48.8 10.5
Sex (% males) 40.9 44.4
Basal serum ereatinine (mg/dl) 6.0 1.6 7.3 1.7
Basal hemoglobin (g!dl)
Hemoglobin at 3 months
8.2 0.9
10.6 1.4"
10.0 1.4
9.8 1.7
+18
Basal hematocrit (%)
Hematocrit at 3 months (%)
Basal OS of SIP
24.6 2.8
31.4 5.3"
17.7 2.4
30.6 4.7
29.2 5.2
12.7 4.6
OS of SIP at 3 months 14.5 2.lc 14.9 2.3
Basal PhD of SIP 16.8 3.0 7.9 4.1
PhD of SIP at 3 months 12.8 2.1c 11.9 3.8
Basal P5D of SIP 16.0 2.2 20.7 6.1
PsD of SIP at 3 months 13.1 1.8w 17.7 3.9
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Table 2. Causes of Epo hyporesponsiveness
Iron deficiency B12/folate deficiency
Absolute Vitamin C deficiency
Functional Malnutrition
Blood loss Immunosuppression
Hyperparathyroidism Chemotherapy
Aluminum intoxication ACE inhibitors?
Inflammatory states Theophylline?
Malignant diseases Bioincompatible dialysis?
Hemolysis Oxalosis
Myelodysplastic syndromes Hypothyroidism
Premature birth
also depends on the clinical status of the patient. We want to know
whether the improvement in the patient's quality of life could
allow us to delay the start of dialysis without producing negative
clinical effects for the patient. At this moment, we have no results,
but we consider the question extremely important because of its
economic consequences. In effect, if Epo treatment allows a delay
in initiation of dialysis with impunity, the cost-benefit ratio will
improve.
The increasing number of publications on pre-dialysis treat-
ment with Epo suggests that the number of patients undergoing
Epo treatment before dialysis is increasing. In the last EDTA
Registry Report [1], the number of pre-dialysis patients receiving
Epo treatment was equivalent to 7% of all dialysis-treated pa-
tients in Europe. It is difficult to know what percentage of
pre-dialysis patients receive Epo, because evaluation of pre-
dialysis patients is not included in the different international
registries of patients.
Finally, one might suppose that the beneficial effects observed
in Epo-treated dialysis patients are the same as those in pre-
dialysis patients. However, prospective studies are necessary to
elucidate whether the beneficial cardiovascular effects of Epo
accrue in pre-dialysis patients. If left-ventricular hypertrophy
could be reversed before a patient starts renal replacement
therapy, overall morbidity and mortality might be improved.
Hyporesponsiveness to eiythropoietin
In the first studies of Epo treatment in dialysis patients, a small
percentage of patients, less than 5%, showed a total or partial
resistance to Epo therapy [11, 20, 211. Now, only eight years later,
many possible causes of an inadequate response to Epo have been
documented (Table 2). The most common cause is an unsus-
pected iron deficiency [22]. The beginning of hemodialysis treat-
ment generally coincides with a rapid decrease in previously
normal iron stores, probably as a consequence of blood loss in the
dialyser and blood lines. On the other hand, iron deficiency does
not always mean that iron stores are diminished. The availability
of iron can be diminished; this situation is known as functional
iron deficiency. The best indicator of iron availability is the
percentage of transferrin saturation [23]. Serum ferritin is a good
index of the amount of iron stored. The best parameter for
determining a real or functional iron deficiency is the percentage
of hypochromic red cells in the peripheral smear. Other param-
eters for monitoring iron deficiency are the transferrin receptor
concentration in blood, red cell ferritin level, free eiythrocyte
protoporphyrin, and red cell zinc protoporphyrin [24—26]. 1 will
comment shortly on clinical aspects of diagnosing iron deficiency
and presenting iron supplementation during Epo treatments. I
will discuss this topic further when describing the optimization of
Epo therapy.
Blood loss is a frequent cause of apparent hyporesponsiveness
to Epo as well as of iron deficiency. Gastrointestinal blood loss, as
well as blood loss during the dialysis procedure, are the most
common causes of hidden bleeding. The increased risk of occult
gastrointestinal bleeding is a consequence of the increased bleed-
ing tendency and of the higher prevalence of gastritis, peptic ulcer,
and gastrointestinal telangiectasia in patients with ESRD. Occult
blood loss must be excluded and gastrointestinal endoscopy is
sometimes necessary. Metrorrhagia also must be taken into
account in women with iron deficiency and Epo hyporesponsive-
ness.
Hyperparathyroidism exacerbates anemia in chronic renal fail-
ure. High levels of parathyroid hormone might have a deleterious
effect on eiythroid progenitors in bone marrow [27, 281, and they
also can increase hemolysis or provoke bone marrow fibrosis
consequent to cystic osteitis fibrosa [29]. Today's patient had
responded adequately to Epo treatment for four years, but when
he developed severe hyperparathyroidism, his anemia increased in
spite of increased doses of Epo. He had no iron deficiency,
aluminum intoxication, or inflammatory or neoplastic disease.
Parathyroidectomy improved the anemia and allowed a lowering
of the Epo dose. These findings have been confirmed in other
patients of ours in whom parathyroidectomy permitted an in-
crease in the hematocrit despite lowered Epo dosing [30]. In seven
of our hemodialysis patients treated with Epo who presented with
severe hyperparathyroidism and were submitted to subtotal para-
thyroidectomy, the mean hematocrit before parathyroidectomy
was 27.9% 5.7%; six months later it increased to 35.1% 6.4%.
These changes permitted lowering the weekly mean Epo dose
from 136 12.5 lU/kg to 94 10.5 lU/kg. Other authors have
made the same observations [29]. Rao et a! showed that the mean
dose of Epo required to maintain a target hematocrit of 35%
3% was 174 33 lU/kg three times weekly in a group of seven
patients with poor response to Epo and severe hyperparathyroid-
ism (mean PTH level of 800 648 pg/mI), versus a group of 11
patients who needed only an Epo dose of 56 18 lU/kg three
times weekly in whom the mean PTH level was 266 322 pg/mI
[29]. These authors also found a correlation between the doses of
Epo needed and the percentage of osteoclastic and eroded bone
surfaces and the degree of bone marrow fibrosis [29]. Experimen-
tal data are not conclusive, however. In effect, some authors
reported an inhibitory effect of PTH on erythroid colony growth
[311; this effect has not been confirmed by others [32, 33]. The
rapid improvement in Epo responsiveness after parathyroidec-
tomy supports the hypothesis that elevated parathyroid hormone
levels have a toxic effect on red cells or on erythroid progenitors.
Aluminum intoxication also blunts the response to Epo. Fortu-
nately, aluminum intoxication is not very frequent nowadays. The
principal source of intoxication is inadequate treatment of water
for dialysis, but phosphate binders also can contribute. Anemia
provoked by aluminum overload is usually normocytic but, in the
case of severe intoxication, it is microcytic. On the other hand,
gastrointestinal aluminum absorption is increased in iron-de-
pleted patients [34]. We must not forget that aluminum and iron
can share common metabolic routes and that each can regulate
uptake of the other. Both are bound to serum transferrin [34].
Aluminum intoxication reduces absorption and cellular uptake of
iron [35]. The diagnostic procedures for aluminum overload
Nephrology Forum: Eiythropoietin in CRF 1377
include the monitoring of serum aluminum concentration and,
above all, a deferoxamine (DFO) test using low doses (5 mg/kg) if
the serum aluminum level exceeds 60 j.tg/liter. Patients with a
positive DFO test have a serum aluminum increment higher than
150 tg/liter and should undergo DFO treatment with the same
dose once weekly. The patient should be dialyzed with high-flux
membranes [361. Therapy with DFO in aluminum-induced resis-
tance to Epo therapy enhances the erythropoietic response to Epo
in dialysis patients [37].
Other common causes preventing a response to Epo are
infections, inflammatory states, and neoplastic diseases. Acute or
chronic infections of bacterial, viral, or fungal origin usually are
accompanied by a lower response to Epo. Many infections are
accompanied by a limited iron availability and a consequent
inability of the patient to produce heme [38]. Occult infections as
well as inflammatory disorders such as rheumatoid arthritis [39],
systemic lupus eythematosus [40], inflammatory bowel disease
[41], and malignant neoplastic diseases [42] can decrease the
response to Epo. An increased production of cytokines seems to
be involved in this decreased response to Epo. In effect, it has
been shown that IL-i, TNFa and interferon y have a suppressor
effect on erythropoiesis. Some studies suggest an effect of these
inflammatory cytokines on endogenous Epo production [43], but
a resistance to the effect of Epo on erythroid progenitor cells also
has been demonstrated [44]. Macdougall recently proved that
IL-6 also lowers response to Epo [45] and that IL-3 and IGF-1
potentiate erythropoiesis [46]. Furthermore, several chronic in-
flammatory diseases also raise serum TNFa and IL-i concentra-
tions [28, 39]. The increase in serum fibrinogen over 4 g/liter is a
good clinical indicator of the presence of an inflammatory process
and of the response to exogenous Epo [25].
Hepatitis B viral infection is one inflammatory disease in which
anemia is not worsened [I; nor is anemia exacerbated in
drug-induced hepatitis or other types of viral hepatitis. Liver
inflammation seems to increase endogenous erythropoietin pro-
duction as a consequence of the capacity of the newly formed
hepatocytes to secrete this hormone [48]. An increase in serum
immunoreactive erythropoietin has been described in anephric
dialysis patients during an episode of acute non-A, non-B hepa-
titis [48]. Hepatitis C viral infection also is accompanied by an
increased responsiveness to exogenous Epo [49]. However, an
increase in serum erythropoietin levels as an index of endogenous
erythropoietin production has not been observed in other reports
[50], despite the improvement of anemia. An alternative explana-
tion could be an increased responsiveness to Epo of the erythroid
cells or the production of some cytokines with erythropoictic
activity such as IGF-1 [50]. Resistance to Epo treatment also has
been reported in an AIDS patient treated with zidovudine (AZT)
[51].
Chronic graft rejection frequently causes chronic renal failure
and can be considered a chronic inflammatory state. It is not
unusual to observe a lack of response to Epo in patients who have
undergone transplantation and who have chronic rejection [52].
Also resistance to Epo treatment has been observed in transplant
patients who returned to hemodialysis; this hyporesponsiveness
can be improved after graft removal [53] or by maintaining
cyclosporine treatment [54]. In these cases, the possible effects of
immunosuppression must be taken into account. I will return to
this topic.
Malignancy must be ruled out in patients who don't respond
adequately to Epo. In a group of 81 patients with solid malignant
tumors, the serum concentration of immunoreactive eiythropoi-
etin decreased, although there was not an absolute inability to
produce erythropoietin because hypoxemia induced adequate
crythropoietin production [42]. Further, immunosuppressive and
chemotherapeutic drugs can interfere with Epo. In fact, chemo-
therapeutic agents further decrease Epo production. This effect is
not only observed with the nephrotoxic agent cis-platinum, but
also with other chemotherapeutic agents [42]. Multiple myeloma
causes ESRD in a small percentage of patients and is usually
accompanied by severe anemia, which can be improved with Epo
therapy, albeit at doses higher than usual [55, 56].
The presence of hemolysis also can decrease a patient's re-
sponse to Epo. The causes of hemolysis are varied, from antibody-
mediated hemolysis to hypersplenism to toxic or mechanical
hemolysis. Hemoglobinopathies, such as thalassemia and sickle-
cell disease, are another frequent cause of hyporesponsiveness to
Epo treatment. In all these processes, red cell destruction pro-
duces a need for higher Epo doses to combat anemia in these
patients [57]. The diagnosis and correction of the cause, when
possible, will improve Epo response. Hydroxyurea can improve
the response to Epo in sickle-cell disease [58]. A resistance to the
response to Epo has been observed in myelodyplastic syndromes
[59] and in premature infants [60].
Vitamin B12 and folic acid deficiency can each aggravate
anemia in ESRD. We do not consider it necessary to administer
vitamin B12 and folic acid supplements to all dialysis patients.
Serum levels of these vitamins are useful for diagnostic purposes.
Some patients with vitamin C deficiency have high levels of serum
ferritin with low transferrin saturation. Vitamin C supplementa-
tion can improve iron availability in patients with functional iron
deficiency [61]. Severe malnutrition also can interfere with Epo
response [62].
Therapeutic agents can induce Epo resistance. Chemotherapy
for malignant disease inhibits erythropoiesis [42]. The effect of
immunosuppressive treatment has been studied in patients who
have received transplants. Cyclosporine A can reduce the endog-
enous secretion of erythropoietin in cultured Hep3B cells [63],
and in phenylhydrazine-induced anemia in mice [64], but no
evidence has shown a decreased response to Epo in patients
receiving cyclosporine A [65]. Furthermore, some patients who
have received a transplant have had an improved response to Epo
treatment after cyclosporine was added to the treatment regimen
[54]. This effect might occur because cyclosporine inhibits cyto-
kine secretion. Azathioprine clearly worsens anemia in patients
who have undergone transplantation [10].
Angiotensin-converting-enzyme (ACE) inhibitors diminish the
production of endogenous erythropoietin in patients with chronic
renal failure of different causes [66], including transplant patients
with chronic renal failure [67, 68]. However, it appears that Epo
requirements are not increased in ESRD patients treated with
ACE inhibitors [69]. We have not found any differences in
hematocrit and hemoglobin levels, or in the weekly doses of Epo,
in hemodialysis patients receiving treatment with ACE inhibitors,
compared to others receiving another antihypertensive therapy or
those receiving no antihypertensive therapy. Other recent studies
also have found no increase in the doses of Epo needed in patients
treated with ACE inhibitors [69].
Theophyllinc, an adenosine antagonist, diminishes the renal
production of Epo and lowers hematocrit [70]. It remains to be
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proved, however, that patients treated with theophylline need
higher doses of Epo.
The literature contains only a few reports on ESRD patients
with oxalosis who have received Epo, but the majority of the cases
show a poor response to the therapy [71]. Hypothyroidism, a
frequent cause of anemia, can worsen anemia in ESRD patients,
necessitating higher doses of Epo [72]. Exogenous thyroid therapy
can improve hypothyroidism, thereby decreasing the Epo require-
ments and raising the hematocrit.
Bioincompatible dialysis membranes result in monocyte activa-
tion and cytokine secretion [73]. But even the use of biocompat-
ible dialysis membranes can be accompanied by an increase in
serum IL-6 and TNFo in the presence of bacterial contamination
of the dialysate [741. Such cytokine activation must be a conse-
quence of the passage of bacterial endotoxins into the blood
through a highly permeable membrane. Therefore, when using
biocompatible (and highly permeable) membranes, one absolutely
must have a sterile dialysate. The possible effect of this cytokine
activation on Epo responsiveness has not yet been studied.
Optimizing the use of Epo
Three important points should be kept in mind when one uses
Epo in patients with ESRD. First, the factors that aggravate
anemia in chronic renal failure, and thus induce hyporesponsive-
ness to Epo, must be eliminated. I have already addressed these
factors (Table 1). Second, iron supplementation must be ade-
quate. This point requires that iron stores be carefully monitored.
Serum ferritin is synthesized in the reticulo-endothelial system
and secreted into the plasma. The rate of ferritin protein synthesis
is governed by the iron concentration in the intracellular iron
pooi, which is related to the intracellular iron stores [75]. When
iron metabolism is balanced, serum ferritin levels reflect the state
of the iron stores. Erythropoietin administration acutely decreases
serum ferritin levels within a few hours of administration [75]. On
the other hand, serum ferritin also can be raised in inflammatory
states, infection, and liver disease [76]. One must keep in mind,
however, that patients can have a functional iron deficiency with
normal or high serum ferritin levels. Transferrin saturation mea-
sures the amount of iron joined to transferrin and, although it is
not related to iron stores, the saturation level provides a more
exact idea of iron availability.
Much attention has recently focused on the percentage of
hypochromic red blood cells (defined as an individual cell hemo-
globin concentration lower than 28 gIdI [26]) as a reliable index of
iron deficiency. When the percentage is higher than 10%, an iron
deficiency (absolute or functional) is present [26, 77]. Other
parameters that seem more exact in diagnosing iron deficiency are
the transferrin receptor concentration in blood, the red cell
ferritin concentration, free eiythrocytc protoporphyrin, and red
cell zinc protoporphyrin. Iron-deficient erythropoiesis can be
recognized by an elevation of serum transferrin receptor concen-
tration [25]. Transferrin receptor concentration, as well as the
percentage of hypochromic red blood cells, are more accurate for
detecting a functional iron deficiency than is the transferrin
saturation level [25, 26]. Red cell ferritin concentration could be
a valid support to serum ferritin evaluation in the determination
of patients with a real iron deficiency erythropoiesis [78]. Free
erythrocyte protoporphyrin level is an early marker of iron
deficiency in nonuremic patients. Increased levels in uremic
patients are a consequence of a defective heme transferrin
receptor concentration [79, 80]. Red cell zinc protoporphyrin is a
poor marker for iron deficiency [80]. Most of these analyses are
not available in the majority of laboratories, however. Although
formulas have been devised for calculating the level of iron
reserves and iron needs in patients to be treated with Epo [22],
clinical experience shows that iron requirements in patients
receiving Epo are higher than those derived from theoretical
calculations.
Erythropoietin should not be given if iron deficiency exists.
Patients must receive iron supplementation before Epo treatment
if the following conditions exist: the serum ferritin is lower than
100 gIml, the transferrin saturation is lower than 20%, or more
than 10% of hypochromic red cells are present. Even with iron
supplementation, serum ferritin levels virtually always decrease
after Epo therapy. In our experience, after six months of Epo
treatment, ferritin levels are at the bottom of the normal range in
patients who have received oral iron supplementation. Further-
more, several years ago we observed that high levels of serum
ferritin decreased significantly after one year of Epo treatment in
renal failure patients with iron overload (polytransfused patients).
There is no doubt that Epo treatment is a good therapy for iron
overload [81].
Controversy exists regarding whether orally administered iron
is adequately absorbed from the gut. Early studies suggested that
iron absorption from the gut was increased in dialysis patients who
were iron deficient [46, 82]. Other studies suggest that iron
absorption increases with Epo therapy [83], but we frequently
observe patients, like today's case presentation, for whom oral
iron administration is insufficient to maintain adequate iron stores
because despite oral iron administration, serum ferritin levels
decrease during Epo therapy; this situation also has been ob-
served by other authors [75], In fact, some studies suggest that
iron absorption is impaired in dialysis patients taking Epo [84].
We usually administer intravenous iron supplementation before
Epo treatment to patients whose serum ferritin levels are lower
than 100 g/liter or who have a transferrin saturation lower than
20% or a percentage of hypochromic red cells higher than 10%. In
these cases, we administer three successive intravenous doses of
62.5 mg of ferrous gluconate during hemodialysis. Periodic mon-
itoring of iron metabolism indicates the frequency of successive
doses of intravenous iron. Similar dosage schedules of intravenous
iron have been proposed by other authors using, in some cases,
iron dextran [46, 84]. In a randomized prospective study on iron
supplementation in renal patients treated with Epo, intravenous
iron was compared with oral iron and no iron supplementation.
Patients receiving regular intravenous iron had a significantly
increased hemoglobin response, better maintained serum ferritin,
and lower Epo dosage requirements [3]. In my opinion, intrave-
nous iron avoids gastrointestinal side effects and poor compliance
with oral iron, as well as possible poor absorption from the gut.
The third important point in optimizing Epo therapy is deter-
mining the best route and dose of administration. The intraperi-
toneal route for peritoneal dialysis patients has the disadvantage
of the low bioavailahility of Epo administered by this route (less
than 10% compared to the intravenous route [7, 85]). However,
some studies show that Epo can be useful when administered by
the intraperitoneal route, if the overnight peritoneal fluid volume
is reduced to one liter and Epo is administered in this fluid [7].
The intraperitoneal route can be useful in patients in whom
subcutaneous administration poses problems, such as peritoneal
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dialysis-treated children. The intravenous route was the first used,
but studies soon showed that the subcutaneous route allowed a
reduction in doses of approximately 30% with similar results [86]
and with considerable economic savings. Other studies confirm
these findings, but most of them are difficult to interpret because
of flaws in study design and methods [87]. Recent prospective,
randomized, cross-over studies show the same elevation of hemo-
globin level whether the Epo is given by intravenous or subcuta-
neous route [88]. Other authors also observed no difference in
hematocrit in patients treated either by intravenous or subcuta-
neous route [89]. In both studies intravenous iron supplementa-
tion was administered [89]. In fact, in Europe, according to the
EDTA Registry Report of 1993 [1], nearly 50% of the dialysis
patients receiving Epo receive the hormone intravenously [1].
There are important variations from one country to the next. In
Austria and Spain, more than 50% of the patients receive Epo by
the intravenous route; in the United Kingdom, the majority of
patients receive the treatment subcutaneously [1].
A conventional starting intravenous dose is 40—50 lU/kg thrice
weekly (2000—4000 lU/dose). When the subcutaneous route is
used, the usual starting dose is 20—30 U/kg thrice weekly (1000—
2000 lU/dose). When the target hematocrit is reached, the doses
can be lowered and a much lower dosage is sufficient to maintain
the desired hematocrit.
The bioavailability of subcutaneously administered Epo is
higher when the injection is made in the thigh compared to the
arm or abdomen [90]. The intravenously administered mainte-
nance dose (when the target hematocrit has been achieved) is best
administered two or three times per week. For the subcutaneous
route, when the weekly dose is low (less than 4000 IU), the entire
dose can be administered at one time. We have not observed
significant variations in hematocrit levels in hemodialysis patients
receiving Epo in three doses per week who later received it in one
weekly dose. In a group of 21 hemodialysis patients, we changed
the dosage schedule from three doses per week to one dose per
week when the mean hematocrit of the patients was 32,5%
3.8%. After 12 months with one dose per week, the mean
hematocrit was 32.5% 3% [91]. Other studies have shown
similar observations [92]. The principal reason for administering
one dose per week is to decrease pain, although the pain is also
related to the amount injected; therefore the one dose per week
regimen is recommended only for patients on a low dose. The
differences observed in the pain produced by epoetin-a (Epo
diluted in an aqueous solution containing sodium chloride, citrate
buffer, and human serum albumin) and epoetin-3 (lyophilized
Epo without citrate buffer and human serum albumin) seem to
disappear when citrate is eliminated as the vehicle in epoetin-a
[7]. In summary, we can conclude that both intravenous and
subcutaneous routes are appropriate for hemodialysis patients,
but that the subcutaneous route is preferable for pre-dialysis or
peritoneal dialysis patients. Regarding a maintenance dosage
schedule, two or three times/week seems to be acceptable and, in
patients receiving a low dose, one weekly dose suffices.
Eschbach has recently emphasized that adjunctive therapies can
increase the efficiency of Epo [721. Among these, the use of
androgenic steroids has been proposed by several authors [93].
Testosterone, nandrolone decanoate, and fluoxymesterone have
been used for this purpose. Economic arguments have been used
to propose their use in developing countries to reduce the Epo
dose and to reach the same results with less cost. However, the
adverse effects of androgenie steroids cannot be disregarded.
Among them, acne, liver disease, elevation of serum triglycerides,
hirsutism, virilization, and priapism have been described [94].
While IL-I and IL-6 inhibit the effect of Epo, IL-3 and IGF-1
stimulate erythroid progenitor cells. Animal studies have demon-
strated that it is possible to decrease the dose of Epo when IL-3
is administered [95]. Interleukin-3 acts with Epo in stimulating
erythroid progenitor cells. In any case, we must consider the
possible toxic effects of IL-3 as well as its cost. It is also not clear
what the possible effect of L-carnitine administration is on
improving the response to Epo [961. Thymopentin, administered
concomitantly with Epo, ameliorates anemia in hemodialysis
patients resistant to Epo therapy alone [97]. More experience is
necessary to evaluate the usefulness of this pentapeptide as an
adjunctive therapy to Epo.
Finally, dialysis efficiency must be taken into account in any
attempt at maximizing the effectiveness of Epo therapy. It is a
well-known fact that the improvement in hemodialysis efficiency
by using high-efficiency or high-flux dialysis is usually accompa-
nied by an improvement in anemia; longer hemodialysis is asso-
ciated with a higher hematoerit [98]. It has not been determined
whether this improvement in anemia is related to better uremic
toxin removal, biocompatibility, or other factors related to dialysis
efficiency. Peritoneal dialysis patients also have higher hematocrit
levels than do patients undergoing conventional hemodialysis,
possibly because of the removal of some larger toxic molecules,
although these patients have higher iron stores because of less
blood loss [72]. Moderate physical exercise also might have a
positive effect on dialysis patients, because regular, fairly strenu-
ous exercise can improve erythropoiesis [99], although the mech-
anism for this has not been clarified.
Beneficial effects
An improved hematocrit in Epo-treated patients provides both
non-cardiovascular and cardiovascular benefits. The non-cardio-
vascular effects include a reduction in fatigue and increased
working capacity and exercise tolerance [100]. Muscular fatigue
during exercise might be caused by ATP or substrate (glycogen)
depletion, by a limited flux of oxygen due to acidosis, alterations
in electrolytes, or insufficient muscle mass [101]. Skeletal muscle
shows a reduced oxidative capacity in chronic renal failure
patients [101], but a normal glycogen content has been found in
the muscle of patients with ESRD [102]. The ATP production
capacity is increased in anemic hemodialysis patients [103]; this
suggests that mitochondrial respiratory capacity does not limit
maximal performance in chronic renal failure. In fact, this in-
crease might be a form of metabolic adaptation to the decrease in
oxygen delivery [103]. The rise in hemoglobin concentration as a
consequence of Epo administration is associated with a rise in
maximal oxygen uptake (V02 max) [104]. Maximal exercise
capacity increases during Epo treatment [105] as does the anaero-
bic threshold.
Coagulation parameters improve. Platelet aggregation, factor
VIII, and fibrinogen levels improve due to the increase in the red
cell mass [106]. These changes, however, might confer a risk of
thrombotic events, such as vascular access clotting and an increase
in the need for heparin during hemodialysis [107]. Long-term
controlled studies do not demonstrate a higher incidence of
thrombotic episodes, however [108]. The usual immunosuppres-
sion of chronic renal failure improves with Epo therapy. A rise in
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blood viscosity can worsen microcirculation and is probably one of
the factors implicated in the peripheral vascular resistance in-
crease that affects these patients. Some studies have shown a
deficit of cognitive function in anemic ESRD patients that can be
assessed psychometrically, such as by the trailmaking test and by
evoked potentials [109]. Evoked potentials are useful in the
evaluation of cognitive brain dysfunction. The elevation of hemat-
ocrit from 22% to 30% during Epo treatment improved stimulus-
related evoked potentials and trailmaking in 15 chronic hemodi-
alysis patients [109]. This improvement in cognitive function could
explain, at least in part, the feeling of well-being and the increase
in working capacity of the patients.
Other non-cardiovascular benefits also accrue with Epo ther-
apy. An improvement in sexual function has been observed,
especially in males [110]. This change in male sexual function
might be due not only to an improvement of anemia, but also to
an increase in serum testosterone levels related to a decrease in
luteinizing hormone [111]. Erythropoietin therapy also can im-
prove appetite, the feeling of well-being, depression, and the
sleep/awake pattern. Raynaud's phenomenon decreases or disap-
pears in some patients. An improvement in the lipid profile of
hemodialysis patients was recently described; serum total choles-
terol, ApoB lipoprotein, and serum triglycerides decrease with
Epo treatment [112]. Finally, cytotoxic antibodies diminish in
sensitized polytransfused patients [113]. We have observed this
phenomenon in 42 patients after two years of Epo treatment in
parallel to the striking decrease in the number of transfusions
[114].
Nutritional status improves in patients treated with Epo [115].
A short-term, randomized study showed an improvement of
pruritis in 10 hemodialysis patients; itching returned after one
week of discontinuation of Epo therapy [116]. This improvement
was not related to the change in hemoglobin level. These patients
had elevated plasma histamine levels, as compared with hemodi-
alysis patients without pruritis and with normal subjects. Therapy
with Epo decreased plasma histamine levels, and recurrence of
pruritus after Epo discontinuation was accompanied by an in-
crease in plasma histamine concentration [116]. Other authors
have seen an improvement of pruritus in hemodialysis patients
treated with an anti-allergic drug (azelastin HCI) without changes
in the plasma histamine levels during azelastin treatment [117].
The cardiovascular effects of Epo therapy are evident in
different short-term studies at one or two years. In ESRD
patients, the prevalence of left-ventricular hypertrophy (LVH) is
between 50% and 80%; the prevailing functional disturbance
associated with LVH is left-ventricular diastolic dysfunction.
Left-ventricular hypertrophy is an important and independent risk
factor for mortality in these patients [118]. On the other hand,
anemia is associated with an increased heart rate and left-
ventricular stroke volume, which result in an elevated cardiac
output, an important stimulus for ventricular hypertrophy. Several
studies have shown an improvement in LVH during Epo treat-
ment. Left-ventricular end-diastolic diameter decreases, as does
interventricular septum thickness and left-ventricular mass index
[119, 120]. In most studies, a reduction of left-ventricular mass
index from 170—190 g/m2 to 130 g/m2 has been observed after 6 to
12 months of Epo treatment [121]. Taking into account that more
than 50% of deaths in ESRD patients are due to cardiovascular
causes [1], and that left-ventricular mass is an important risk
factor for mortality in these patients, it is reasonable to anticipate
that LVH reduction with Epo therapy will improve long-term
survival [122]. In one study, the survival of ESRD patients with a
left-ventricular muscle index lower than 125 g/m2 was significantly
better at five-year followup compared to that in patients with a
left-ventricular muscle index higher than 125 g/m2 [118]. How-
ever, the hypothesis of an improvement of patient survival after
Epo treatment has not yet been substantiated. Cardiac output
decreases as a consequence of stroke volume decrease or heart
rate reduction [119, 123, 124]. Another beneficial effect of Epo
treatment is the reduction in the incidence of angina in patients
with coronary heart disease after anemia is corrected [125].
Peripheral vascular resistance increases markedly in parallel
with a reduction of cardiac output [123, 126, 127]. This elevated
systemic peripheral resistance is the main cause of hypertension in
patients receiving Epo (see later). Several factors can contribute
to increased peripheral vascular resistance. The increased blood
viscosity can contribute to this effect [128] as well as to the
improvement of hypoxia, which would decrease hypoxic vasodila-
tion. Erythropoietin also increases pressor responsiveness to
noradrenaline and angiotensin 11 and improves the anemia-
mediated disturbance of alpha-2 receptor function [129]. Alpha-2
adrenoceptor density and plasma catecholamines are increased in
ESRD patients, who likely have a defective receptor-ligand
interaction [129]. When anemia is corrected by Epo therapy, both
catecholamine concentration and aipha-adrenoceptor density de-
creased and vascular resistance increased [129]. Lastly, the in-
crease in vascular resistance has been related to an elevation of
platelet cytosolic free Ca [130] and to increased endothelin-1
production [131]. Figure 2 summarizes the potential mechanisms
involved in Epo-related hypertension.
Total blood volume remains constant, but plasma volume
decreases during Epo therapy. The decrease in plasma volume
can influence hemodialysis efficiency, although significant varia-
tions have not been reported in studies using urea kinetic mod-
eling [132]. The incidence of hemodialysis-related hypotension
decreases in parallel with the correction of anemia [133], probably
as a consequence of the improvement of the autonomic nervous
system dysfunction observed during Epo therapy [134].
Hypertension was the most frequent adverse effect in the early
experience with Epo treatment, appearing in previously normo-
tensive patients or in those with worsening pre-existing hyperten-
sion; the prevalence rate can reach 30% [135]. More recently,
however, probably because of less-aggressive dosage schedules,
the reported prevalence of hypertension is about 20% [122].
Hypertension that develops during Epo treatment and worsening
of previously existing hypertension generally arc easy to control
via a careful adjustment of the hemodialysis patient's "dry
weight," initiation of antihypertensive therapy, or an adjustment
of the dosage schedule of the antihypertensivc agents previously
used. The improvement in appetite usually is a cause of weight
gain in dialysis patients treated with Epo. A reduction in dry
weight by removal of fluid during dialysis can be sufficient to
control hypertension. If this is not sufficient, antihypertensive
agents must be added or, if the patient was previously under
antihypertensive treatment, the doses must be increased or an-
other agent must be introduced. Epo doses can be reduced, but
only in very exceptional cases must Epo therapy be stopped.
Eiythropoietin imposes no contraindications for any specific drug;
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Fig. 2. Mechanisms involved in Epo-related
hypertension. Epo induces an increase in blood
viscosity, plasma catecholamine levels, platelet
cytosolic free calcium, and endothelin-1
production. The pressor response to
noradrenaline (Na) and angiotensin II (Ang II)
improves, as does the alpha-2 adrenoccptor
defect. Hypoxic vasodilation decreases, and Epo
probably has a direct vascular effect. All these
facts may contribute to the increase of
peripheral vascular resistance. Epo improves
appetite, thus possibly inducing weight gain.
The decrease of cardiac output is overrun by
the increase of peripheral vascular resistance,
and arterial hypertension appears or worsens in
the previously hypertensive patient.
neither ACE inhibitors nor calcium antagonists are contraindi-
cated. One recent study showed a 5.8% prevalence of hyperten-
sion in 34 hemodialysis patients under Epo treatment who also
were receiving antiplatelet therapy; in another group of 57
hemodialysis patients receiving Epo but not antiplatelet therapy,
the prevalence of hypertension was 56%. The antiplatelet drugs
received by the patients studied were ditazole, ticlopidine, and
dipyridamole plus aspirin [136]. There is no clear explanation for
this beneficial effect of antiplatelet therapy in Epo-related hyper-
tension; one can infer that changes in platelet aggregability
induced by Epo might be involved in the pathogenesis of Epo-
related hypertension. Other adverse effects, such as thrombotic
events, clotting of the vascular access, seizures, and cerebrovas-
cular accidents, have a similar prevalence to that observed in
non-Epo-treated patients [135].
Quality of life seems to improve in patients receiving Epo.
Several studies using quality of life questionnaires have reported
significant improvement [137—139]. Our own prospective study
evaluated quality of life in hemodialysis patients with ESRD, both
before starting Epo treatment and at three and six months after
therapy was begun [140]. A control group of "non-anemic pa-
tients" was studied. The tests used for this study were the
Karnofsky Performance Scale (KS) and the Sickness Impact
Profile (SIP). The KS is a well-known and simple global indicator
of self-sufficiency and functional capacity [141]. The SIP, a more
complex questionnaire, is based on criteria that evaluate dysfunc-
tional behavior related to the illness [142]. It comprises 136 items
in 12 activity categories in which dysfunctional behavior can occur.
The 12 categories are grouped to obtain physical and psychosocial
dimensions and a global SIP score. In this study, we used the
Spanish version of the SIP, done by F. Moreno, adapted from the
"Spanish" version by W. Hendricson [143] for our environment.
We observed a significant improvement in the KS as well as in the
physical and psychosocial dimensions and the global SIP score at
three and six months in a group of 57 non-diabetic hemodialysis
patients treated with Epo, whose mean hematocrit increased from
21.03% 0.3% to 29.0% 0.4%, after six months; we did not
Epo group Control group
Number 57 29
Mean age (years) 50 2 53 2
Basal hematocrit (%)
Hematocrit at 6 months (%)
21.0 0.3
29.0 0.4"
30.0 0.8
31.0 0.8
Basal KS score 68.4 1.8 79.7 2.6
KS score at 6 months 81.0 1.4" 76.9 2.6
Basal GS of the SIP 19.8 1.6 16.6 2.4
GS of the SIP at 6 months 13.5 1.2" 15.1 2.2
Basal PhD of the SIP 15.4 1.8 11.6 2.4
PhD of the SIP at 6 months 9.6 1.4 10.6 2.5
Basal PsD of the SIP 19.0 1.9 16.0 3.0
PsD of the SIP at 6 months 10.8 1.3" 14.3 2.9
Diabetic patients were not included in either group. (From Ref. 140).
Data as mean standard error of mean. KS, Karnofsky scale; SIP,
sickness impact profile; GS, global score; PhD, physical dimension; PsD,
psychosocial dimension. Higher KS scores mean better quality of life.
Lower SIP scores mean better quality of life.
bp < 0.0001.
detect a similar response in the control group of 29 hemodialysis
patients not treated with Epo whose mean hematocrit was 30.0%
0.8% before starting the study, and 31.0% 0.8% after six
months [140] (Table 3). We used a multivariate analysis by
stepwise linear regression to evaluate improvement in specific
factors related to the quality of life. Improvement in quality of life
was inversely related to the basal quality of life indicators; patients
with a worse clinical condition before treatment experienced a
more intense feeling of improvement. Work disability before Epo
treatment is also related to a higher improvement in quality of life,
probably because work disability may be an indicator of poor
quality of life. The hematocrit at six months of treatment also was
related to an improvement in quality of life. Co-morbidity,
measured by the index proposed by Friedman [1441, was another
factor related to a poor quality of life [140].
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Table 3. Hematocrit and quality-of-life scores in a group of
hemodialysis patients treated with Epo and a control group of
hemodialysis patients not receiving Epoa
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Fig. 3. Relation between quality-of 7ifi scores and
hernatocrit. The Karnofsky scale scores and the
physical dimension of the Sickness Impact
Profile scores are better in patients with higher
9- hematocrit. This effect is particularly evident
with hematocrits higher than 29% (In the
Karnofsky scale, higher scores mean better
quality of life, and in the Sickness Impact
Profile, lower scores mean better quality of
life.) 5P < 0.01. (Results were obtained from
275 quality-of-life questionnaires filled Out by
102 hemodialysis patients. Scores are
represented as mean SD. From Ref. 148.)
A Spanish cross-sectional multicenter study of 1013 dialysis
patients showed that the principal factors related to quality of life
are age, co-morbidity and, again, hemoglobin and hematocrit
levels [145, 1461. Other factors related to a better quality of life
are higher socioeconomic and cultural levels. Diabetes, female
gender, and intermittent claudication related to a lower quality of
life. Patients with hemogloblin levels over 12 g!dl had significantly
higher quality-of-life scores. These differences were observed both
in the physical and psychosocial dimensions as well as in the global
score of the SIP. Although this study evaluated more than 1000
patients, no relationship was observed between quality of life and
dialysis technique (conventional hemodialysis, hemodiafiltration,
or peritoneal dialysis), the use of synthetic or cellulosic mem-
branes, or bicarbonate or acetate hemodialysis. No relationship
was observed between quality of life and dialysis efficiency (as
measured by KT/V), or protein intake, measured by protein
catabolic rate (PCR). In any case, we must not forget that this
study was cross-sectional and that the patients had not been
randomly assigned to a particular technique. Prospective studies
are necessary to clarify whether dialysis efficiency and biocompat-
ihility (including biocompatibility of dialysate) have an influence
on quality of life.
The target hematocrit
Our own study first yielded firm evidence that quality of life
improved during Epo treatment when the hematocrit level rose.
Although aged patients had a higher co-morbidity index, a group
of 23 non-diabetic hemodialysis patients older than 60 years had
a significant improvement in quality-of-life scores measured by
the KS and SIP, in parallel with their hematocrit increase during
Epo therapy [1401. A similar improvement in quality-of-life scores
also was observed in 15 patients older than 65 years [140, 147].
This is an important finding: age is not a contraindication for Epo
treatment.
What should the target hematocrit be for patients receiving
Epo? This is one of the controversies related to EPO treatment.
In Europe, according to the EDTA Registry, 50% of the centers
had a target hemoglobin level between 9.5 g!dl and 10.4 g!dl, hut
the percentage of centers reporting higher target hemoglobin
levels (10.5 g/dl—1 1.4 g!dl) is increasing [11 The target hemoglobin
and hematocrit levels usually have been chosen empirically.
Unfortunately, at present, there are no long-term morbidity and
mortality studies relating to hematocrit in patients receiving Epo.
Currently, the best available index for deciding target hematocrit
is based on quality of life and working capacity. A Canadian
multicenter study showed a small improvement in quality of life
and exercise capacity in patients with a mean hemoglobin level of
12 g!dl [137]. As I mentioned, in our own experience, hematocrit
level is one of the factors related to the improvement in quality of
life [1461.
In another study using the same KS and SIP instruments, we
showed a direct relationship between hematocrit and quality of
life scores. We compared KS and SIP scores for 57 hemodialysis
patients receiving Epo treatment and 29 untreated patients with
various hematocrits. Both groups were matched for age and
co-morbidity. The physical dimension of the SIP (as well as the
global score and the KS) improved markedly at hematocrits
ranging from 29% to over 35%. The KS and SIP scores were
similar in patients with hematocrits up to 29%, but with hemat-
ocrits higher than 31%, a direct relationship existed between
hematocrit and the quality-of-life scores. This relationship did not
disappear at the higher hematocrit levels (Fig. 3). We concluded
that a direct relationship exists between quality of life and
hematocrit, which was preserved even at the higher hematocrit
levels [148].
Other authors have measured maximum oxygen supply to the
brain at different hematocrit levels during Epo treatment [1491.
They calculated the maximum oxygen supply to the brain from
measurements of regional cerebral blood flow using positron
emission tomography and arterial oxygen content. The optimal
hematocrit for maximum oxygen supply in this study was around
40%. Eschbach et a! increased Epo doses to raise hematocrit from
a mean of 32.6% to 42% in 13 hemodialysis patients and noted a
significant improvement in quality of life, exercise capacity, and
cardiac function [150]. Cardiac output decreased from 5.1 liter!
mm to 4.3 liter!min, exercise duration increased by 20%, and
maximal oxygen consumption increased by 24%. There were no
adverse effects. However, the mean increase in Epo dose was 69%
[150].
We can summarize by saying that a conventional target hemat-
ocrit of about 30%, or a target hemoglobin of about 9 gldl, must
be considered insufficient. One might reasonably consider that the
conventional normal hematocrit should be the target hematocrit
for patients with ESRD. However, the biggest problem in obtain-
ing a "normal" hematocrit in ESRD patients is the increase in the
required dose of Epo and therefore the cost of treatment, It is
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probable that the most reasonable position is to individualize
target hematocrit. Young patients who carry out physical activities
or patients with heart disease would need a nearly normal
hematocrit. However, older patients without heart disease or
sedentary patients would not need such high hematocrit levels.
Eschbach's idea of letting patients decide what hematocrit is best
for them is very enticing [72] and would rationalize the idea of
individualizing target hematocrit. Erythropoietin therapy must be
individually optimized to achieve maximal benefits at a lower cost.
Can Epo treatment lengthen survival?
The long-term benefits of Epo have not been determined. A
recent study showed that anemia can predict mortality in ESRD
patients independently of age, presence of diabetes, cardiac
failure, serum albumin and creatinine levels, blood pressure, and
cardiac disease [1511. Anemia increases left-ventricular end-
diastolic diameter, which promotes LVH [151], and LVH in-
creases mortality by more than three times in hemodialyis patients
1152]. Thus correcting anemia and therefore normalizing cardiac
size and decreasing cardiac output should improve survival in
patients with ESRD. Patients with polycystic kidney disease have
a better survival rate than do other ESRD patients [1531, and
patients with polycystic kidney disease have higher levels of
hemoglobin [153]. We should seriously consider the recently
made suggestion that we should "adapt the dialysis unit to
increased hematocrit levels" [1541, because sufficient evidence
now indicates that higher hematocrits reduce long-term morbidity
and mortality. Finally, Epo therapy can reverse many uremic
(probably, in large part, anemic) symptoms and improve the
quality of life of chronic renal failure patients before dialysis and
after dialysis is initiated, It is not an exaggeration to say that Epo
has been the most prominent medical advance in the treatment of
ESRD patients since maintenance dialysis treatment was intro-
duced 36 years ago.
Questions and answers
DR. NIcoLAos E. MADIAS (Chief Division of Wephrology, New
England Medical Center, Boston, Massachusetts, USA.): Regres-
sion of left-ventricular hypertrophy following Epo treatment is
obviously of great clinical importance. How rigorously has this
effect been documented and how consistent is it? Has it been
dissociated from the effect of certain antihypertensive medica-
tions, which by themselves can lead to regression of cardiac
hypertrophy?
DR. VALDERRABANO: The best answer to your question would
have been evidence that Epo therapy decreases the long-term
cardiovascular mortality rate in dialysis patients. But we have no
evidence of that. Two factors could reduce left-ventricular hyper-
trophy. One is the improvement of anemia. It is well proven that
the improvement of anemia with Epo decreases left-ventricular
hypertrophy [119—121 ], and that this effect is independent of the
effect of antihypertensive agents, such as ACE inhibitors or
calcium antagonists. The second factor is hypertension. We must
he especially careful to achieve excellent control of hypertension
when treating dialysis patients with Epo. If hypertension is well
controlled, left-ventricular hypertrophy will improve and ventric-
ular mass will decrease [155]. But the balance between anemia
and hypertension must be carefully maintained. On the other
hand, anemia per se is an independent mortality risk factor,
irrespective of left-ventricular hypertrophy or hypertension [151].
This means that we must take both factors into account to achieve
the best results from Epo treatment.
DR. F. PAOLO SCIIENA (Institute of Nephrolo, Polyclinic, Ban,
Italy): Do you believe that it is important to measure endogenous
(native) Epo in uremic patients undergoing periodic dialysis
before starting Epo treatment, since this therapy is very expen-
sive?
DR. VALDERRABANO: From the practical point of view, it is not
necessary to have serum Epo levels before starting treatment with
Epo. Of course, to maintain a positive cost-benefit relation, the
optimal use of Epo is fundamental. Thus therapy should include
adequate iron monitoring and iron supplementation, correct
dosage of Epo, and the exclusion of all the causes of Epo
hyporesponsiveness. In the majority of eases, knowing the pre-
treatment Epo level is not necessary because it is not predictive of
the response to exogenous Epo.
DR. SCHENA: Does Epo treatment improve graft survival in
uremic patients who receive Epo therapy before renal transplan-
tation?
DR. VALDERRABANO: I do not know of any studies regarding the
effect of Epo therapy before transplantation on graft survival. I
should note that azathioprine decreases the response to Epo [10].
On the other hand, cyclosporine does not have this effect; in fact,
cyclosporine sometimes improves the response to Epo, likely
because it decreases cytokine production [54]. More and more
pre-dialysis patients are treated with Epo, and one of the causes of
end-stage renal disease, and thus starting dialysis, is a failed renal
graft. Erythropoietin does not seem to hasten the progression of
renal dysfunction in such patients. However, we need prospective
and controlled studies to clarify this point.
DR. FERNANDO CARRERA (Department of Nephrology, Hospital
SAMS, Lisbon, Portugal): Is there a correlation among level of
anemia, need for Epo, and the type of dialysis membrane used? If
so, is there any relation between quality of life and the type of
dialysis membranes used?
DR. VALDERRABANO: The use of high-permeability and biocom-
patible membranes, as well as longer hemodialysis sessions, has
been associated with higher hematocrit in patients not treated
with Epo [98]. 1 don't know of any correlation between quality of
life and the type of membrane used. Moreover, in the multicenter
study carried out in Spain, more than 1000 patients were included,
and no relationship was apparent between quality of life and the
type of dialysis membrane used [145]. We expected to find a
higher quality of life in patients treated with the more sophisti-
cated, more expensive, and more advanced dialysis techniques,
that is, biocompatible membranes, hemodiafiltration, and other
techniques. However, this is not what we found. A possible
explanation is that this study was retrospective and not random-
ized; it was a cross-sectional study.
DR. DONALD SILVERBFRG (Department of Nephrology, Tel Aviv
Medical Center, Tel Aviv, Israel): Did you obtain blood pressure
data showing no change in blood pressure in Epo administration
with 24-hour blood pressure monitoring or just with usual blood
pressure measurements obtained in the clinic? Recent 24-hour
blood pressure studies have shown almost uniform elevation of
blood pressure with Epo, particularly at night [156].
DR. VALDERRABANO: We measured our patients' blood pressure
during dialysis sessions or at office visits. We did not do 24-hour
blood pressure monitoring on our patients. Twenty-four hour
blood pressure monitoring is the best method of evaluating blood
1384 Nephrology Fonim: Eiythropoietin in CRF
pressure control in any hypertensive patient as well as the
efficiency and safety of any antihypertensive drug [156]. In my
opinion, the problem you raised seems to be related to the type of
antihypertensive agent used more than to the hypertensive action
of Epo.
DR. SILVERBERG: To what level do you increase ferritin or
transferrin saturation in pre-dialysis or hemodialysis patients? If
you had increased ferritin to 400 sg/liter before giving Epo, would
you have achieved the same elevation of hematocrit as with Epo?
DR. VALDERRABANO: One of the main ways of improving a
patient's reponse to Epo is with intravenous iron repletion [3, 46,
84]. We also must monitor the patient to prevent iron overload. In
our experience and in published studies [46], intravenous iron
administration produces no adverse effects if the transferrin
saturation and ferritin levels are periodically monitored. Isolated
administration of iron without Epo does not achieve the same
elevation of hematocrit, and in this situation there is a risk of iron
overload. In your paper, you showed an increase of hematocrit
from 29.4 3.2% to 32.4 2.2% in a group of 22 pre-dialysis
patients treated with 200 mg of intravenous ferric saccharate, once
monthly for five months, without additional Epo treatment [157].
In these 22 patients, the mean serum ferritin level increased from
94 81 sgIliter to 296 172 pg/liter. The experience in
pre-dialysis patients treated with Epo and with oral iron supple-
mentation showed higher increments in hematocrit [4, 5] than that
described administering only I.V. iron supplements.
DR. SILVERBERO: Could you clarify the parameters that guide
iron administration?
DR. VALDERRABANO: A ferritin level lower than 100 jsg/liter or
transferrin saturation lower than 20% indicates iron deficiency.
Several intravenous iron doses are necessary to replete iron
stores. When the serum ferritin level is higher than 100 sgIliter or
transferrin saturation higher than 20%, we continue administering
intravenous iron at a different dosage; that is, we give 62.5 mg of
ferrous gluconate once weekly, once every two weeks, or once per
month according to the serum ferritin levels. Also we monitor the
serum ferritin level and avoid ferritin levels above 300 jig/liter.
DR. SILVERBERG: You said a subcutaneous Epo dose is more
effective than one given intravenously in hemodialysis patients.
Yet studies have shown that if the level of ferritin is equal, the
response to the two methods is similar [88].
DR. VALDERRABAN0: This problem has not been fully clarified.
Several studies have shown that lower doses administered subcu-
taneously can produce similar results as higher intravenous doses
[86, 158]. However, recent cross-over randomized studies showed
a similar response whether Epo is given intravenously or subcu-
taneously [87, 88].
DR. FRANTJSEK KOKOT (Professor of Medicine, Department of
Nephrology, Silesian University of Medicine, Katowice, Poland):
You stressed the problem of hyporesponsiveness to Epo. As you
know, there is a small population of patients who are hyperrespon-
sive to Epo, in whom, in spite of discontinued Epo administration,
the hematocrit is maintained or even increased for several
months. Of course, in these patients the presence of a renal cyst
cannot be excluded. Could you comment on the problem of
hyperresponsiveness to Epo in hemodialyis patients without renal
cysts?
DR. VALDERRABANO: This problem was reported in the case you
recently published, in which renal cysts were not present [159]. I
had a similar experience, but in patients with renal cysts. We
stopped giving Epo to two patients treated with Epo for more
than one year, because the hematocrit level exceeded 50%. Six
months later, both patients' hematocrits exceeded 40% without
Epo treatment or iron supplementation. Both of our patients had
acquired cystic disease in their native kidneys. The serum Epo
levels in these two patients were normal for their hematocrit
levels, Serum Epo levels in dialysis patients before treatment with
Epo are lower than those observed in healthy controls when
correlated with their hematocrit or hemoglobin levels [18]. Our
two patients with renal cysts had normal serum Epo levels and
normal hematocrits, but there are many other dialysis patients
with acquired cystic disease who are anemic. I have not seen
hyperresponsiveness to Epo in other patients.
DR. MADIAS: Your data suggest that administration of Epo to
pre-dialysis patients retards the progression of renal disease.
Given the various shortcomings of using the 1/Cr ratio as an index
of GFR, do you know of any studies on progression that have used
direct measurements of GFR?
DR. VALDERRABANO: Yes, a 1994 study shows that renal func-
tion did not worsen in pre-dialysis patients treated with Epo [17].
The authors measured the GFR with '25I-iothalamate. The ma-
jority of the studies in humans monitored renal function by the
slope of the inverse of serum creatinine, but these did not find a
decline in renal function in pre-dialysis patients receiving Epo
when they periodically measured GFR.
DR. PIETRO ZUCCHELLI (Professor of Medicine, Malpighi Depart-
ment of Nephrology, S. Orsola-Malpighi Hospital, Bologna, Italy):
You said that Epo can reverse left-ventricular hypertrophy and
that data suggest that left-ventricular hypertrophy and left-ven-
tricular diastolic dysfunction are the main causes of hemodialysis-
related hypotension. Have you data on Epo's effect on the
frequency of hemodialysis-related hypotension?
DR. VALDERRABANO: I mentioned a decrease in the frequency
of hemodialysis-related hypotension as a beneficial effect of Epo
(unpublished observations). Our own patients have experienced
this effect, and they tolerate hemodialysis better. Patients with
severe anemia are prone to hemodialysis-related hypotension, and
Epo improved hemodialysis-related hypotension in a group of
hemodialysis patients [133]. In this study, however, the patients
were also shifted from acetate hemodialysis to bicarbonate hemo-
dialysis, and it is well known that bicarbonate hemodialysis
improves dialysis tolerance. The improvement of hemodialysis
tolerance during Epo treatment might be explained through the
improvement of anemia itself or through the different vascular
effects of this hormone, which increases peripheral vascular
resistance (see Fig. 2). On the other hand, hemodialysis-related
hypotension also is related to the autonomic nervous system
dysfunction existing in end-stage renal disease, and this dysfunc-
tion improves during Epo therapy [134]. In fact, Epo therapy
significantly raised the blood pressure in a group of 8 patients with
non-renal disease and orthostatic hypotension (4 patients with
type-I diabetes mellitus and autonomic neuropathy, 3 patients
with pure autonomic failure, and one patient with sympathotonic
orthostatic hypotension) at a dose of 50 lU/kg thrice weekly [160].
On the other hand, London et al showed that Epo not only
improved left-ventricular end-diastolic diameter, but also signifi-
cantly increased the venous tone [127]. This venoconstriction
observed during correction of anemia with Epo contributes to an
adequate venous return and cardiac filling [127]. All these factors
might participate in the improvement of hemodialysis-related
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hypotension, although other authors did not find any change in
the incidence of hypotensive episodes in hemodialysis patients
receiving Epo in spite of an increase in the total peripheral
resistance index of 623% [161].
DR. JORGE CANNATA (Professor of Medicine, Head of the Re-
search Unit, Hospital Central de Asturias, Oviedo University, Oviedo,
Spain): I want to come back to a practical point, that is, the target
hematocrit level in patients receiving Epo. According to the data
you have shown from the EDTA Registry, it seems that 50% of
the European centers have selected a target hematocrit of around
30%. Looking at your results on quality of life, it seems that it
should be useful to raise the hematocrit higher. Is this a useful or
safe policy as a general practice in dialysis units?
DR. VALDERRABANO: Approximately 50% of European centers
are using a conventional target hematocrit of about 30%, but the
EDTA Registry report also showed a significant number of
centers using higher target hematocrit levels. The main question
regarding the target hematocrit is, why isn't a normal hematocrit
the target hematocrit? If a relatively healthy person feels poorly
with a low hematocrit, why shouldn't a patient with end-stage
renal failure? The main reason for individualizing the target
hematocrit is the high cost of erythropoietin. Eschbach ci al
showed in 13 hemodialysis patients that increasing Epo doses
significantly raised the hematocrit in some patients, hut most of
these patients needed a greater than 60% increment in the dose of
Epo to achieve a heinatocrit higher than 40% [1501. This means
that the cost of treatment was increased significantly. Young
patients doing physical exercise require a higher hematocrit level.
But this is not the case with old patients living a sedentary life. In
these cases it is probably not necessary to increase the hematocrit
to the same levels as in more active patients. On the other hand,
angina can occur at different hematocrit levels for any patient, and
the objective should be to maintain the patient free of symptoms.
Finally, we must not forget that a clear relationship between the
hematocrit level achieved during Epo treatment and the incidence
of adverse effects (that is, hypertension) has not been reported.
DR. JOSEPH W. ESCHBACH (Professor of Medicine, University of
Washington, Minor and James Medical Clinic, Seattle, Washington,
U.S.A.): Thank you, Fernando, for your excellent review today.
My question relates to the issue of how to optimize the hem atocrit
and the dose for our patients. Why is there a range in which
patients respond to a given Epo dose? Is this variation in response
any different between subcutaneous or intravenous route of
administration? In general, is there a need for more Epo after the
initiation of hemodialysis compared with a stable dose adminis-
tered prior to dialysis? Epo dose requirements vary, even in the
absence of obvious reasons. At what upper dose of Epo do you
look for causes of "resistance?"
DR. VALDERRABANO: These are very good questions; I do not
know whether I have good answers. It is usual to start with a
conventional dose for all patients. Our practice is always to
administer iron if iron parameters are low, so that the patient has
good iron repletion before starting Epo therapy. The iron level is
one of the main factors related to Epo response. After Epo
treatment has been started, it is difficult to determine all the
factors involved in the various responses observed in different
patients. The different causes of hyporesponsiveness (absolute or
functional iron deficiency, blood loss, hyperparathyroidism, alu-
minum overload, presence of inflammation, hemolysis, cytokine
activation, etc.) can be present in each patient but with a different
intensity. In consequence, these can be the factors involved in the
different response to Epo. A different response to a standard dose
occurs when Epo is given by the intravenous or subcutaneous
route. In general, dialysis patients treated via the subcutaneous
route responded more slowly than did those in whom the intra-
venous route was used, although final results were similar. With
regard to a possible change in the dose of Epo needed when a
pre-dialysis patient starts dialysis, this change is not necessary if
iron supplementation is adequate. We must take into account that
iron needs usually increase after hemodialysis begins, probably as
a consequence of higher blood loss. Finally, it is not clear at which
dose of Epo one must search for a cause of hyporesponsiveness.
We must bear in mind all possible causes of hyporresponsiveness
in every Epo-treated patient. If the patient does not respond well
after the induction period, we must exclude the major causes of
Epo resistance.
DR. NETAR P. MALLICK (Professor of Medicine, Manchester Royal
Infirinaty, University of Manchester, Manchester, UK): How do
age, activity level, and co-morbidity influence the time of initiation
and target level for Epo?
DR. VALDERRABANO: In the multicenter Spanish study on
quality of uk in hemodialysis patients, the main factors related to
quality of life were age and co-morbidity [145]. The older the age,
the worse was the quality of life of the patient. But an improve-
ment in quality ot life has been observed in different age groups of
patients, including patients older than 65, when the hematocrit
increases during Epo treatment [140]. Young patients improve,
but older patients also can improve. In consequence, there is a
clear indication for treatment in elderly patients. Co-morbidity is
the other main factor related to quality of life in hemodialysis
patients. A third factor is hematocrit or hemoglobin level. We
cannot change the age of the patient, nor can we alter the
morbidity of the patient, but we can improve the hematocrit and
thus the quality of life. The target hematocrit will depend on
physical activity, and usually elderly patients have less physical
activity than do younger patients.
DR. MADIAS: You have all but discarded any effect of ACE
inhibitors on Epo levels and the anemia of chronic renal failure.
Yet, as you know, there are well-documented interrelationships
between the renin-angiotensin axis and erythropoietin. What
observations have been made on the effects of ACE inhibitors on
erythropoietin levels and anemia in pre-dialysis and dialysis
patients?
DR. VALDERRABANO: Patients with chronic renal failure from
different primary renal diseases, including chronic graft rejection,
had lower serum levels of endogenous Epo and more anemia
when treated with ACE inhibitors [66—69]. In our experience and
in published studies, these patients do not need higher doses of
Epo, and this is also the case for dialysis patients treated with
ACE inhibitors [69]. Low endogenous Epo levels do not seem to
influence the patient's response to exogenous Epo. In conse-
quence, these patients can he treated with ACE inhibitors without
interfering with their response to Epo.
DR. GIOVANNI SELVAGGI Assistant in Nephrology, Fatebene-
fratelli Hospital, Rome, Italy): Is it possible that the long-term use
of Epo and the consequent overstimulation of bone marrow can
cause dyserythropoietic anemia or leukemia? Have you ever
observed anti-Epo antibodies?
DR. VALDERRABANO: Myeloproliferative syndromes have not
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been reported as a consequence of Epo treatment. I have never
observed anti-Epo antibodies in any patient.
DR. VLADIMIR TEPLAN (Associate Professor of Medicine, Depart-
ment of Nephrology, Institute for Clinical and Experimental Medi-
cine, Prague, Czech Republic): How can we improve the nutritional
status (malnutrition) of patients with chronic renal failure and
anemia who ingest a low-protein diet and take low doses of Epo?
DR. VALDERRABANO: Nutritional assessment in hemodialysis
patients treated with Epo showed art improvement in nutritional
parameters [115]. This improvement seems to be related to an
increase in appetite in these patients. Similarly, in malnourished
pre-dialysis patients, Epo can increase appetite; in consequence,
the nutritional state can improve. In these cases, the potential
benefit of a low-protein diet on the progression of renal failure is
probably less important for the outcome of the patient than is
general nutrition, which is the most important risk factor for
morbidity and mortality in patients with end-stage renal failure.
DR. ARTS D. EFSTRATOPOULOS (Professor of Medicine, Athens
General Hospital, Athens, Greece): Let's return to the target
hematocrit. You said that the higher the hematocrit, the better the
quality of life; however, we have to take into account that
increasing the hematocrit more than 33% to 35% produces more
frequent hypertension and increases the platelet count, and
probably the platelets' ability to aggregate as well. These two
factors can worsen cardiovascular morbidity and mortality, mainly
stroke and myocardial infarction, in the long term.
DR. VALDERRABANO: A relationship between the incidence of
hypertension and hematocrit levels has not been described. Nor
has an elevation in either platelet count or incidence of cardio-
vascular accidents been observed in studies analyzing the effect of
normalization of hematocrit with Epo treatment [150]. However,
the beneficial effect of increasing the hematocrit over 35% must
be achieved with strict control of hypertension.
DR. JER-MING CHANG (Attending Physician, Division of Nephrol-
ogy, Kaohsiung Medical College, Kaohsiung, Taiwan): You said that
you don't recommend iron supplementation during Epo treat-
ment if the plasma ferritin level is greater than 200 jsglliter. Yet
papers published several years ago, using iron stain of bone
marrow biopsies as a standard for evaluating the adequacy of iron
stores, found that the serum ferritin level must be at least 300
gIliter to ensure the adequacy of iron stores [162]. Another
recently published paper also supported this concept [163]. Some
patients with serum ferritin levels greater than 1000 .tg/liter still
had inadequate iron stores [164]. What is your opinion?
DR. VALDERRABANO: Here we have two different issues: the
amount of iron stores, and the availability of iron to be utilized by
bone marrow. Serum ferritin is a good index of iron stores, and
the amount of iron stained on the bone marrow can add infor-
mation, but we also need information on the availability of iron.
The best way to monitor iron metabolism is to determine serum
ferritin levels so that one can know the state of iron stores,
transferrin saturation (which gives information about iron avail-
ability to bone marrow), and the percentage of hypochromic red
cells, the best index of absolute or functional iron deficiency.
Serum ferritin is not the best parameter for iron metabolism
evaluation. Several papers have shown that the erythrocyte fer-
ritin level might be a more reliable way to estimate the actual iron
status in patients whose serum ferritin levels are misleadingly
elevated as a consequence of chronic inflammatory processes or
liver disease [78, 1621.
Another study carried out on 65 hemodialysis patients found a
resistance to Epo when serum ferritin levels were lower than 300
jLg/liter [163]. However, it is unusual to observe Epo resistance
when serum ferritin levels are lower than 300 sglliter. Other
causes of Epo hyporesponsiveness must be ruled out in any
patient with normal serum ferritin levels.
DR. ESCHBACH: I would like to pursue the last question. There
is the perception that iron deficiency can exist despite very high
serum ferritin levels [163]. These authors evaluated bone marrow
iron stores using decalcified bone biopsies of autopsied iron-
overloaded dialysis patients. Chelating agents that decalcify bone
generally remove iron as well, although the authors claim that that
had not occurred. Because of their findings, the perception has
existed that bone-marrow iron stores can be depleted in the face
of high serum ferritin levels, and therefore, serum ferritin levels
do not reflect marrow iron needs. However, most other studies
have shown a good correlation between serum ferritin levels and
bone marrow iron as semi-quantitated by Prussian blue iron
stains. Iron stores, as reflected by the serum ferritin, are also
inversely related to iron absorption, the latter increasing signifi-
cantly when the serum ferritin level decreases to below 30 sg/liter
[165]. Therefore, to maintain adequate iron stores, the serum
ferritin should be kept above 100 sg/liter with oral or intravenous
iron therapy. However, since the advent of Epo therapy, iron
absorption might not be adequate to meet the iron needs for most
hemodialysis patients because of the non-physiologic, pharmaco-
logic doses that intravenous Epo provides. But when Epo is given
subcutaneously, in which case the peak serum Epo level can be
one-tenth of that given intravenously, there may not be as much
demand by the marrow for iron, in which case oral iron therapy
may be adequate. In my experience, most hemodialysis patients
getting intravenous Epo require intravenous iron, whereas predi-
alysis and peritoneal dialysis patients treated with subcutaneous
Epo, and who also don't have the tremendous iron (blood) losses
of hemodialysis patients, often can maintain iron stores with oral
iron alone. I would appreciate knowing your experience as to
whether oral iron can maintain iron stores in hemodialysis pa-
tients treated with subcutaneous Epo.
DR. VALDERRABANO: Your question has several interesting
aspects. One is the route of administration of Epo in hemodialysis
patients. We have not found differences in iron needs between
patients receiving erythropoietin by the subcutaneous route and
those receiving it intravenously. I absolutely agree that CAPD and
pre-dialysis patients only need intravenous iron occasionally. The
patient presented today is an exception because he developed iron
deficiency, with very low levels of ferritin, after a few months of
treatment. But this patient had a nephrotic syndrome, and it is
probable that some other factor such as edema of the gastroin-
testinal mucosa interfered with iron absorption in this patient. In
the majority of pre-dialysis and peritoneal dialysis patients, oral
iron supplementation will be enough. But in hemodialysis pa-
tients, intravenous iron supplementation is more efficient than
oral, improves the response to Epo, and is a safe way to replace
iron stores [46].
DR. KA5I VISWESWARAN (Professor of Nephrology, Medical Col-
lege, Kottayam, India): Would you advocate the use of low-dose
Epo therapy in a young patient with chronic renal failure who is
not going to receive chronic hemodialysis or renal transplanta-
tion? Such a scenario is very common in many developing
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countries. Does the improvement in quality of life justify the use
of low-dose subcutaneous Epo?
DR. VALDERRABANO: Do you mean in patients with end-stage
renal disease who are not going to start renal replacement
therapy? In my country there are very few contraindications for
starting renal replacement therapy. But in patients in whom, for
different reasons, renal replacement therapy was not indicated, we
have given low-dose Epo subcutaneously, and these patients were
less symptomatic and had a better quality of life than before
treatment. This is one indication for Epo therapy in developing
countries where renal replacement therapy is not possible for all
patients who need it.
DR. BARUCH HURWICH (Shaare Zedek Hospital, Jerusalem, Isra-
el): Certainly Epo is one of the most exciting developments since
the beginning of chronic dialysis. Little discussion has addressed
the rather long list of complications, however, some of which are
serious, such as thrombosis of the fistula and myocardial infarc-
tion. Is there a way to identify these high-risk patients?
DR. VALDERRABANO: If we carefully monitor hypertension,
which is the main adverse effect of Epo therapy, the other adverse
effects are not a big problem. Some controlled prospective studies
showed no differences in the incidence of clotting of vascular
access in patients treated with Epo compared with hemodialysis
patients not treated with Epo [108]. We have a policy of preven-
tion of clotting of vascular access. When a hemodialysis blood flow
of 350 ml/min cannot be achieved, or return blood pressure
increases over 150 mm Hg, we routinely obtain a fistulogram. In
the majority of cases, we find a stenosis that must be corrected.
With our preventive approach, we have found no difference in the
incidence or thrombosis of the vascular access in patients treated
with Epo compared with patients not receiving the hormone.
Regarding myocardial infarction and cerebrovascular accident, no
evidence indicates that these frequent complications in end-stage
renal disease patients are more likely to appear in patients treated
with Epo.
DR. MENELAOS PAPADIMITRIOU (Professor of Medicine and Ne-
phrology, Department of Nephrology, Aristotelian University, Thes-
saloniki, Greece): Let's come back to the case presentation. I was
surprised that this patient did not become hypertensive even
though his hematocrit rose dramatically after he became hyper-
calcemic. Therefore I would assume that he might have been
taking antihypertensive therapy or that he is an exceptional case.
Second, you did not mention his levels of blood urea and urinary
urea excretion, which would indicate his nitrogen balance before
and after Epo treatment. Before dialysis, the patient did not show
any significant change in blood urea and urinary urea excretion.
DR. VALDERRABANO: I selected this case for two interesting
reasons: the patient's need for intravenous iron during pre-dialysis
Epo therapy, and resistance to Epo as a consequence of severe
hyperparathyroidism during hemodialysis. During the several
years that the patient was on hemodialysis, his hypertension was
well controlled with antihypertensive agents. He only became
hypercalcemic three weeks after starting treatment with intrave-
nous calcitriol. Hypercalcemia is a frequent complication of
calcitriol administered either orally or intravenously, especially
when severe hyperparathyroidism exists, as in this patient. In our
general experience, calcitriol-induced hypercalcemia is not always
accompanied by hypertension. It is also interesting that this
patient had an idiopathic membranous nephropathy and that he
was normotensive during the first years of evolution of his
nephropathy. This patient also was treated with cyclosporine A
without any beneficial effect on the evolution of the nephropathy.
During the pre-dialysis stage, when the patient was receiving Epo
therapy, we did not see variations in his blood urea levels or in his
urinary urea excretion.
DR. NORMAN LASKER (New Jersey College of Medicine, Newark,
New Jersey, USA.): I would like to address the last question. Dr.
Papadimitriou was questioning why the patient's blood pressure
did not rise with the excessively high hematocrit. We reported in
a letter to the New England Journal of Medicine a contrary
experience: in effect, many patients became hypertensive during
Epo therapy without having an increase in hematocrit [166].
Other mechanisms must be involved, contrary to the popular
theory about the increase in blood volume. Without going into
great detail, the popular theory of the mechanism of hypertension
with Epo therapy is that the blood pressure rises because of an
increase of blood viscosity and blood volume. We identified many
patients whose hematocrit did not rise but who did in fact become
hypertensive while receiving Epo therapy. Also, I would like to
respectfully disagree with Dr. Eschbach's perception that pre-
dialysis and CAPD patients require less iron supplementation. I
think it is just a matter of iron balance.
DR. VALDERRABANO: Your arguments favor a direct vascular
effect of Epo in the genesis of Epo-related hypertension. In your
letter you mentioned that your patients did not have an increase
in hematocrit, body weight, or fluid overload, but that they
became hypertensive during Epo therapy [166]. Your findings do
suggest a direct vascular effect of Epo, although some authors did
not find hypertension after Epo infusion into arterioles [1671.
However, a more recent publication demonstrated that intra-
arterial Epo infusion constricted renal and mesenteric vascular
beds [168].
On the other hand, we must take into account the other
mechanisms involved in Epo-related hypertension, such as the
increase in blood viscosity [128], the increase of cytosolic free
calcium in platelets [130], the increased production of endothe-
lin-1 [131], and the loss of hypoxic vasodilation [169], which seem
to be directly related to an increase in hematocrit.
DR. THOMAS MATHEW (Professor of Nephrology, Government
Medical College, Calicu4 India): What are the commonest reasons
for discontinuing treatment with Epo? Arid generally when do
these occur?
DR. VALDERRABANO: Some of our Epo-treated patients have
had seizures. All of these patients had a history of seizures; in one
case we had to stop Epo treatment two months after starting
therapy. Our first patient treated with Epo had intense musculo-
skeletal pain coinciding with the intravenous injection of Epo, and
we stopped Epo treatment four months after starting. This patient
also had severe hyperparathyroidism. She underwent parathyroid-
ectomy, and her musculoskeletal pain disappeared completely; we
then reintroduced Epo treatment without any trouble. We have
never stopped Epo therapy due to uncontrolled hypertension.
With careful control of dry weight and adjustment of antihyper-
tensive treatment, one rarely needs to stop Epo therapy. In
another case we temporarily stopped Epo treatment after the
patient had a cerebrovascular accident. The patient recovered and
we continued the Epo.
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